HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma.

doi:10.1158/1078-0432.CCR-21-3622

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2022

Sasame Jo, Ikegaya Naoki, Kawazu Masahito, Natsumeda Manabu, Hayashi Takahiro, Isoda Masataka, Satomi Kaishi, Tomiyama Arata, Oshima Akito, Honma Hirokuni, Miyake Yohei, Takabayashi Katsuhiro, Nakamura Taishi, Ueno Toshihide, Matsushita Yuko, Iwashita Hiromichi, Kanemaru Yu, Murata Hidetoshi, Ryo Akihide, Terashima Keita, Yamanaka Shoji, Fujii Yukihiko, Mano Hiroyuki, Komori Takashi, Ichimura Koichi, Cahill Daniel P, Wakimoto Hiroaki, Yamamoto Tetsuya, Tateishi Kensuke

Abstract excerpt

PURPOSE: Molecular targeted therapy using BRAF and/or MEK inhibitors has been applied to BRAFV600E-mutant high-grade gliomas (HGG); however, the therapeutic effect is limited by the emergence of drug resistance. EXPERIMENTAL DESIGN: We established multiple paired BRAFV600E-mutant HGG patient-derived xenograft models based on tissues collected prior to and at relapse after molecular targeted therapy. Using these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to HSP90 Heat-Shock Proteins

Share to Melanoma

Share to Mitogen-Activated Protein Kinase Kinases

Share to Molecular Targeted Therapy

Share to Neoplasm Recurrence, Local

Share to Proto-Oncogene Proteins c-akt

Source

Open in PubMed

Identifiers

PMID: 35344043
DOI: 10.1158/1078-0432.CCR-21-3622

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma.PMID 35344043Read ↗

Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.Semantic proximity Read ↗

Targeted therapy for malignant glioma patients: lessons learned and the road ahead.Semantic proximity Read ↗

Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network.Semantic proximity Read ↗

Forestalling BRAF-Inhibitor Resistance in a Shocking Way.Semantic proximity Read ↗

Activity of the heat shock protein 90 inhibitor ganetespib in melanoma.Semantic proximity Read ↗

Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors.Semantic proximity Read ↗

Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas.Semantic proximity Read ↗

Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922.Semantic proximity Read ↗

Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.Semantic proximity Read ↗

Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor TrametinibSemantic proximity Read ↗

Chaperone directed heterobifunctional molecules circumvent KRASG12C inhibitor resistance.Semantic proximity Read ↗

Resistance mechanisms in BRAFV600E paediatric high-grade glioma and current therapeutic approachesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.